Skip to main content

Table 2 Characteristics of MPV reconstruction patients stratified by venous patent or thrombosed

From: Feasibility of mesentericoportal vein reconstruction by autologous falciform ligament during pancreaticoduodenectomy—cohort study

Variable

All patients (n = 146)

Patent (n = 109)

Thrombosed (n = 37)

P-value

Age, year, median (range)

62 (42–82)

63 (42–82)

60 (43–78)

0.052

Male, n (%)

76 (52.1)

58 (53.2)

18 (48.6)

0.631

MPV reconstruction technique, n (%)

   

0.008

 FL

13 (8.9)

13 (11.9)

0 (0.0)

 

 Primary

30 (20.5)

27 (24.8)

3 (8.1)

 

 LV

19 (13.0)

13 (11.9)

6 (16.2)

 

 PTFE

24 (16.4)

13 (11.9)

11 (29.7)

 

 IA

47 (32.2)

32 (29.4)

15 (40.5)

 

 PV

13 (8.9)

11 (10.1)

2 (5.4)

 

Operation time, min, median (range)

515 (242–921)

450 (242–790)

680 (250–921)

0.000

Blood loss, ml, median (range)

463 (100–2000)

415 (100–1500)

581 (100–2000)

0.037

Intraoperative transfusion, n (%)

25 (17.1)

15 (13.8)

10 (27.0)

0.064

Postoperative pathology

Tumor differentiation, n (%)

   

0.514

 Poor

82 (56.2)

63 (57.8)

19 (51.4)

 

 Moderate

62 (42.5)

44 (40.4)

18 (48.6)

 

 Well

2 (1.4)

2 (1.8)

0 (0.0)

 

Tumor size, cm, median (range)

3.4 (1–10)

3.4 (1–10)

3.4 (1–8)

0.919

Lymph node metastasis, n (%)

88 (60.3)

60 (55.0)

28 (75.7)

0.027

R0 resection, n (%)

129 (88.4)

97 (89.0)

32 (86.5)

0.682

Postoperative complications, n (%)

Pancreatic fistula

28 (19.2)

16 (14.7)

12 (32.4)

0.018

Bleed

11 (7.5)

5 (4.6)

6 (16.2)

0.031

Delayed gastric emptying

13 (8.9)

10 (9.2)

3 (8.1)

0.844

Postoperative abdominal infection

13 (8.9)

7 (6.4)

6 (16.2)

0.071

Unplanned relaparotomy, n (%)

8 (5.5)

3 (2.8)

5 (13.5)

0.025

Mortality within 90 days, n (%)

3 (2.1)

2 (1.8)

1 (2.7)

1.000

Antiplatelet/anticoagulation, n (%)

78 (53.4)

57 (52.3)

21 (56.8)

0.638

Postoperative hospital stay, day, median (range)

21.4 (10–62)

19.5 (10–49)

25.7 (10–62)

0.026

  1. MPV mesentericoportal vein, FL falciform ligament, LV lateral venorrhaphy, PTFE polytetrafluoroethylene, IA iliac artery, PV portal vein